The increase in selling, general and administrative expenses for the six months ended June 30, 2026 compared to the same period in 2025 was primarily due to increases in personnel costs, professional services expenses, travel expenses and non-cash share-based compensation expense.

filing / Aug 12, 2026 / receipt

The increase in personnel costs and other expenses for the three months ended June 30, 2026 compared to the same period in 2025 was primarily due to increases in headcount costs to support our ongoing clinical trials.

filing / Aug 12, 2026 / receipt

The increase in personnel costs and other expenses for the six months ended June 30, 2026 compared to the same period in 2025 was primarily due to increases in headcount costs to support our ongoing clinical trials.

filing / Aug 12, 2026 / receipt

Our San Diego research and development, lab, and principal executive office space lease entered into in January 2025 and amended in June 2025 provides (i) $ 2.4 million in rent credits, and (ii) a $ 6.2 million tenant improvement allowance expected to be fully received in the second half of 2026.

filing / Aug 12, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize KOMZIFTI or any other approved product.

filing / Aug 12, 2026 / receipt

The increase in personnel costs and other expenses for the three months ended March 31, 2026 compared to the same period in 2025 was primarily due to increases in headcount costs to support our ongoing clinical trials.

filing / May 12, 2026 / receipt

Our San Diego research and development, lab, and principal executive office space lease entered into in January 2025 and amended in June 2025 provides (i) $ 2.4 million in rent credits, and (ii) a $ 6.2 million tenant improvement allowance expected to be received during 2026.

filing / May 12, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize KOMZIFTI or any other approved product.

filing / May 12, 2026 / receipt

Oncology Account Manager - Indianapolis/KY/IL | {"ats": "greenhouse", "city": null, "state": null, "job_id": "6192076004", "remote": false, "category": "sales_expansion", "function": "sales", "locatio

company_statement / Sep 15, 2026 / receipt

Vice President, Quality Assurance | {"ats": "greenhouse", "city": "San Diego", "state": "CA", "job_id": "6191507004", "remote": false, "category": "other", "function": "executive", "location": "San Di

company_statement / Sep 14, 2026 / receipt

Associate Director, Medical & Regulatory Writing | {"ats": "greenhouse", "city": null, "state": null, "job_id": "6175236004", "remote": true, "category": "other", "function": "legal", "location": "Rem

company_statement / Sep 11, 2026 / receipt

Assoc Director/Director, IT | {"ats": "greenhouse", "city": "San Diego", "state": "CA", "job_id": "6184395004", "remote": false, "category": "other", "function": "engineering", "location": "San Diego,

company_statement / Sep 11, 2026 / receipt